XOMA Corporation(XOMA)

Description: XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor. Its proprietary products include gevokizumab, a human engineering (HE) antibody to interleukin-1 beta, which is Phase III studies for non-infectious uveitis and Behçet's uveitis; and Phase II studies for inflammatory acne, erosive osteoarthritis of the hand, active non-infectious anterior scleritis, and cardiovascular diseases. The company's proprietary products also comprise XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for diabetes, metabolic disorders, and other orphan indications; XOMA 3AB, a multi-antibody product, which is in Phase I trial for botulism poisoning; and preclinical programs for autoimmune, cardio-metabolic, infectious, inflammatory, ophthalmological, and oncological diseases. In addition, it develops FDC1, a perindopril arginine and amlodipine besylate, which has completed Phase III trial for hypertension; HCD122 and LFA102 programs that are in Phase I and II, and Phase I trials for hematologic tumors, breast and prostate cancers, and other undisclosed diseases; human monoclonal antibodies, which are in preclinical stage for undisclosed disease targets; and therapeutic antibodies that are in Phase II and Phase I trials for non-small cell lung cancer, solid tumors, and multiple myeloma. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; AVEO Pharmaceuticals, Inc.; UCB Celltech; and Genentech, Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

---

Keywords: Medicine Diabetes Infectious Diseases Immunology Solid Tumors Immune System Antibodies Monoclonal Antibodies Prostate Cancer Hypertension Antibody Allergy Cardiovascular Disease Non Small Cell Lung Cancer Osteoarthritis Multiple Myeloma Small Cell Lung Cancer Acne Vascular Disease Metabolic Disorders Inflammatory Platform Technologies Uveitis Takeda Pharmaceutical Company Botulism Human Monoclonal Antibodies Antibody Product Angiotensin Angiotensin Converting Enzyme Non Infectious Uveitis Oncological Diseases

---

Home Page: www.xoma.com

XOMA Technical Analysis

2200 Powell Street
EmeryVille, CA 94608
United States
Phone: 510 204 7200

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)